Risk factors for neuropathic pain in diabetes mellitus
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
1. Introduction According to the International Diabetes Federation, diabetes mellitus (DM) is estimated to affect around 415 million adults worldwide, roughly 8.8% of the adult population, with the figure projected to rise to over 600 million by 2040.20 Regional prevalence varies from 3.2% in Africa to 12.9% in North America. Diabetes mellitus is associated with a number of chronic sequelae and around 50% of people with DM go on to develop polyneuropathy.35 This condition has a variety of clinical manifestations, which are grouped into positive symptoms including dysesthesia (abnormal sense of touch), tingling and itching, and negative symptoms including numbness, muscle weakness, and trouble with balance. Up to 25% of people with diabetic neuropathy (DN) also develop neuropathic pain (NP).39 Neuropathic pain is defined by the International Association for The Study of Pain as “pain directly caused by a lesion or disease affecting the somatosensory system.”12,22 Symptoms of painful diabetic neuropathy (PDN) include those described above for nonpainful DN with additional “burning,” “electric shocks,” “stabbing,” and “pins and needles” symptoms all being described. Painful diabetic neuropathy is associated with increased distress and poor quality of life compared with nonpainful DN, DM, and the general population38 including depression, anxiety, and sleep disturbance.15 In addition, an association has been described with reduced productivity and employability at work compared with nonpainful DN.37 The combination of these factors places a large economic burden on patients and health care services,10 a situation likely to grow steadily worse with the aforementioned projected rise in DM prevalence. This situation is further exacerbated by the fact that 13% of patients with PDN do not report their symptoms to primary care, and 39% of patients with PDN have never received treatment.8 Even for those patients who do attend primary and secondary care for their diabetes, pain is not a symptom that is always included in clinical assessments. Furthermore, not all patients with DN develop PDN, and the reasons for this are unclear. Understanding the risk factors for PDN will go some way to resolving this and will also help to inform management and prevention of this painful condition by health care services. Any factor that increases the risk of DM or DN is likely to be a risk factor for PDN. However, it is the specific nature and magnitude of the risk that remains unclear and is the focus of this topical review. 2. Risk factors There have been relatively few published studies examining risk factors specifically for PDN in DM. Clinical, environmental, and genetic factors have been shown to be predictive of developing DM and some of these have also been implicated in the development of DN, including age,11 body mass index,25,28 hypertension,13 smoking, and waist circumference28 (Fig. 1). Given the likely overlap of risk factors between DM and DN, it seems reasonable to hypothesize that some of these factors will also influence the development of PDN.Figure 1.: Schematic of the process from diabetes mellitus to diabetic neuropathy and finally painful diabetic neuropathy. Both diabetes mellitus and diabetic neuropathy have their own set of risk factors, both of which could provide important clues as to the risk factors that contribute to painful diabetic neuropathy.We conducted a literature search using relevant key words and terms aiming to identify a wide range of studies that investigated risk factors for PDN and to include all the important studies (Table 1). A number of limitations can be identified with these studies as a whole. Most of these studies are cross sectional in nature and therefore unable to establish temporal relationship between patient characteristics/factors and PDN. Some studies report only univariate analysis and are therefore unable to assess intervariable relationships and to identify confounding between variables.2,6,8,9,17,23,30 In addition, it is not always clear in the methods and statistical analyses whether PDN or nonpainful DN is being analysed and what control group the PDN subjects are being compared with. In some studies, those in the control group are diabetic participants with nonpainful neuropathy30,38,41 and in others they are diabetic participants without neuropathy of any form.1,2,6,8,11,17 In other studies, it is not possible to determine the nature of the control group from the description of the methods. There was considerable heterogeneity in PDN case ascertainment, with only 6 studies using a validated NP screening questionnaire (the DN46,7,17,21,38 or the Leeds assessment of neuropathic symptoms and signs11) with the remainder using nonvalidated questionnaires or clinical examinations. This makes it difficult to assess the sensitivity and specificity of each study to identify PDN cases and to make direct comparisons between studies as effect size estimations and associations a
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
The Type 1 Diabetes Genetics Consortium, Barrett, J. C., Clayton, D. G., Concannon, P., Akolkar, B., Cooper, J. D., Erlich, H. A., Julier, C., Morahan, G., Nerup, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.381 · Cited by 1,746
Neuropathic pain: an updated grading system for research and clinical practice
Finnerup, N. B., Haroutounian, S., Kamerman, P., Baron, R., Bennett, D. L. H., Bouhassira, D., Cruccu, G., Freeman, R., Hansson, P., Nurmikko, T., et al. (2016) · Pain · doi:10.1097/j.pain.0000000000000492 · Cited by 1,332
Self-citationAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L., Tai, K.-S., & Stacey, B. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.04.009 · Cited by 525 · cited 2×
“Increased depression, anxiety, enjoyment of life, and social relationships are associated with PDN, but without prospective studies and longitudinal analysis, the temporal relationship cannot be established.(7,15) Figure 1.”
BackgroundZiegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00555.x · Cited by 249 · cited 1×
“Body mass index has been clearly linked to PDN, particularly in the form of obesity ($30 kg/m(2)),(21,33,38) while in another study, weight was reported independently of height and found to be significantly associated with PDN, although this was attenuated in multivariate analysis.(42) A related study also found a pos…”
ResultD’Amato, C., Morganti, R., Greco, C., Di Gennaro, F., Cacciotti, L., Longo, S., Mataluni, G., Lauro, D., Marfia, G. A., & Spallone, V. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116653240 · Cited by 83
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Neuropathic Pain: From Mechanisms to Treatment
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021) · Physiological Reviews · doi:10.1152/physrev.00045.2019 · Cited by 1,558
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Challenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Gylfadottir, S. S., Christensen, D. H., Nicolaisen, S. K., Andersen, H., Callaghan, B. C., Itani, M., Khan, K. S., Kristensen, A. G., Nielsen, J. S., Sindrup, S. H., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001744 · Cited by 151
“Our associations of female sex, smoking, higher BMI, and longer duration of diabetes with DPN in recently diagnosed type 2 diabetes corroborate previous studies of patients with longstanding diabetes.23,27,44 However, in contrast to some previous studies, we only observed an association of painful DPN with smoking sta…”
ResultInfluential
Metadata
- Authors
- Hébert, H. L., Veluchamy, A., Torrance, N., & Smith, B. H.
- Venue
- Pain
- Published
- 2016-12-07
- Volume
- 158
- Issue
- 4
- Pages
- 560-568
- ISSN
- 0304-3959 (ISSN-L)
- 1872-6623
- OpenAlex
- W2560049155
- Cited by
- 117
- References
- 7
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk factors for neuropathic pain in diabetes mellitus. https://app.cochat.ai/papers/10.1097/j.pain.0000000000000785
- The paper
- Hébert, H. L., Veluchamy, A., Torrance, N., & Smith, B. H. (2017). Risk factors for neuropathic pain in diabetes mellitus. Pain. https://doi.org/10.1097/j.pain.0000000000000785
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.